<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In the phase III AZA-001 trial, low-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (LDara-C), the most widely used low-dose chemotherapy in patients with higher-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) who are ineligible for intensive treatment, was found to be associated with poorer survival compared with <z:chebi fb="0" ids="2038">azacitidine</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>This analysis further compared the efficacy and the toxicity of these two drug regimens </plain></SENT>
<SENT sid="2" pm="."><plain>Before randomization, investigators preselected patients to receive a conventional care regimen, one of which was LDara-C </plain></SENT>
<SENT sid="3" pm="."><plain>Of 94 patients preselected to LDara-C, 45 were randomized to <z:chebi fb="0" ids="2038">azacitidine</z:chebi> and 49 to LDara-C </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="2038">Azacitidine</z:chebi> patients had significantly more and longer haematological responses and increased red blood cell transfusion independence </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="2038">Azacitidine</z:chebi> prolonged overall survival versus LDara-C in patients with poor cytogenetic risk, presence of -7/del(7q), and French-American-British subtypes refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation </plain></SENT>
<SENT sid="6" pm="."><plain>When analyzed per patient year of drug exposure, <z:chebi fb="0" ids="2038">azacitidine</z:chebi> treatment was associated with fewer grade 3-4 cytopenias and shorter hospitalisation time than LDara-C in these higher-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
</text></document>